Sleep Quality and Amyloid-Beta Kinetics
Phase: NA
Conditions: Amyloid-beta
Sponsor: Washington University School of Medicine

1 
Version  15_03MAR2020 
 
SLEEP QUALITY AND HUMAN AMYLOID-BETA KINETICS 
NCT:  NCT03077620 
DATE:  MARCH 3, 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2 
Version  15_03MAR2020 
HSC Protocol: 
Sleep Quality and Human Amyloid-Beta Kinetics 
 
Background 
Alzheimer’s disease (AD) is a growing public health crisis with over 5 million Americans 
currently afflicted. With no disease-modifying or prevention treatments for AD, this number is 
predicted to increase to 13.5 million by 2050 (29). Even a modest reduction in AD risk in our 
aging population would have a tremendous impact on public health: delaying the onset of AD by 
5 years would halve disease prevalence. The amyloid hypothesis supports that amyloid-β (Aβ) 
deposition in the brain is a key first-step in AD pathogenesis (30). Changes of 25-40% in Aβ 
production have been shown to completely protect or cause AD in humans (31, 32), therefore Aβ 
has become a primary target for therapies to prevent AD.  
Recent evidence supports a role for sleep in the development of AD, at least in part, via an 
Aβ mechanism. There is a diurnal pattern in Aβ levels in both mice and humans: levels are higher 
in the brain interstitial fluid (ISF) of mice and in human cerebrospinal fluid (CSF) during 
wakefulness and lower during sleep (6, 8). Experimental evidence has also shown that Aβ levels 
are modifiable under different sleep conditions (8). My research translated these findings to 
humans, showing that sleep deprivation increases CSF Aβ40 and Aβ42 compared to participants 
treated with a sleep-inducing medication or those with normal sleep (control). Further, 
preliminary data suggests that higher sleep efficiency (total sleep time/time in bed) is associated 
with a reduction in Aβ concentration in both the sleep-induced with drug and control groups. 
These findings suggest the potential to prevent or delay AD by decreasing CSF Aβ concentrations 
with therapies that improve sleep efficiency.  
This study proposes to directly assess CSF Aβ kinetics (i.e. production and clearance rates) 
and concentration in humans with good vs. poor sleep efficiency and their response to 
pharmacologic sleep induction.  We hypothesize that 1) poor sleep efficiency increases CSF Aβ 
production and concentration compared to good sleep efficiency, and 2) sleep induction in 
individuals with poor sleep efficiency will decrease CSF Aβ production and concentration.  
Specific Aims 1 and 2 will address each hypothesis: 
 
Specific Aim 1:  To determine the effect of poor sleep efficiency on central nervous system 
(CNS) Aβ kinetics.  Cognitively normal adults aged 45-65 with poor sleep efficiency of <85% 
measured by actigraphy (N=15) and good sleep efficiency of >85% measured by actigraphy 
(N=15) will be compared.   Sleep will be monitored with polysomnography (PSG) over 48 hours. 
CSF will be sampled via lumbar catheter every 2 hours.  Each participant will be treated with 
placebo and infused with a stable isotope labeled amino acid for determination of CNS Aβ 
kinetics (e.g. production and clearance) and concentration.  
Hypothesis 1:  Cognitively normal adults with poor sleep efficiency will have increased 
Aβ production and concentration compared to cognitively normal adults with good sleep 
efficiency. 
 
Specific Aim 2:  To determine the effect of pharmacologic sleep induction on CNS Aβ 
kinetics in individuals with poor sleep efficiency.  Participants from Aim 1 with poor sleep 
efficiency treated with placebo (N=15) will be compared to cognitively normal adults aged 45-65 
with poor sleep efficiency treated with a dual orexin receptor antagonist (suvorexant) at 10 mg 
(N=15) and at 20 mg (N=15). CSF sampling frequency, sleep monitoring, and stable isotope 
labeled amino acid infusion for determination of CNS Aβ kinetics and concentration will be the 
same as in Aim 1.  
Hypothesis 2:  Sleep induction with suvorexant in participants with poor sleep efficiency 
will decrease Aβ production and concentration in a dose-dependent manner compared to 
placebo. 

3 
Version  15_03MAR2020 
 
Impact:  My long-term goal is to become an independent physician-scientist investigating the 
relationship between sleep, aging, and AD. My preliminary data shows that sleep deprivation 
increases CNS Aβ concentration and production, but was not designed to answer how differences 
in sleep efficiency alter CNS Aβ. The proposed work will test the hypothesis that CNS Aβ 
kinetics and concentration are increased with low sleep efficiency and modifiable by medication 
to improve sleep efficiency. Answering these questions will provide the scientific foundation to 
support sleep-mediated AD prevention trials. Treatment of AD is hypothesized to be most 
successful in the presymptomatic phase before Aβ deposition into insoluble extracellular amyloid 
plaques and intracellular tau aggregation into tangles causes significant cell death leading to 
cognitive impairment and dementia.  The study will increase our understanding of AD 
pathogenesis, and suggest innovative AD prevention and treatment approaches that involve sleep 
therapies in older adults with poor sleep quality. Sleep problems are common in older adults with 
nearly ALL having changes in sleep architecture, suggesting that improving sleep efficiency in 
older adults may have broad application.  Further, these studies may launch a novel field of 
research that identifies new sleep-based targets for AD treatment. 
 
Experiment:   
Participants:  To investigate the effect of modulating/treating sleep efficiency on Aβ, we 
will recruit 60 participants age 45-65 from a database of >10,000 research volunteers maintained 
at Washington University (Volunteers for Health).  All participants will be screened for normal 
cognitive function (Mini-Mental Status  
Examination score ≥27 (42)).  All participants will be evaluated for sleep disorders by history and 
questionnaires, such as for sleep apnea with the STOP-Bang (43) and insomnia with the Insomnia 
Severity Index (ISI) (44).  For the ISI, a score of 0-7  
indicates no clinically significant insomnia, 8-14 is subthreshold insomnia, 15-21 is moderate 
insomnia, and 22-28 is severe insomnia.  Participants will be screened for sleep efficiency with 
actigraphy (see below).  See Table 2 for all inclusion/exclusion criteria. 
Baseline sleep quality assessment:  Participants meeting the inclusion/exclusion criteria described 
above will then be assessed for sleep efficiency at home with sleep diaries and actigraphy 
(Actiwatch2TM; Respironics, Bend, OR) for two weeks. In the case of a subject currently 
receiving medication that would interfere with the accuracy of sleep efficiency assessment in the 
opinion of the investigator, the participant will be asked to washout of the medication prior to 
baseline actigraphy collection.  The minimum discontinuation period for washout is generally 9 
half-lives of the medication, but will be determined by the investigator.   
 Sleep diaries and actigraphy are well-established methods for assessing sleep at home, and 
are methods we have used previously. Participants an average sleep efficiency of  >85% over the 
two week period will be considered to have “good” sleep quality; participants with an average 
sleep efficiency <85% will be determined to have “poor” sleep quality.  We have set our sleep 
efficiency cut offs for poor and good sleep quality higher than used in our preliminary data 
because of the differences in measuring sleep efficiency by actigraphy compared to PSG.  
Actigraphy over-estimates sleep efficiency compared to PSG (45), therefore higher cutoffs will 
be used when screening with actigraphy. 
 
Sleep quality assessment prior to admission:  Participants meeting enrollment criteria will 
be scheduled for an office visit 7 ± 3 days prior to admission at the Clinical Research Unit.  
Participants will be dispensed a sleep diary and an actiwatch.  They will be asked to continue the 
sleep diary and actigraphy collection until the day of discharge at the Clinical Research Unit.   
 
Aim 1:  To determine the effect of poor sleep efficiency on CNS Aβ kinetics. 
15 participants with sleep efficiency >85% and 15 participants with sleep efficiency <85% 
measured by actigraphy will be admitted to the CRU at Washington University in the afternoon 

4 
Version  15_03MAR2020 
(Day 1)). All participants will have their sleep monitored with PSG (ex. TrackItTM; Lifelines, 
Troy, IL) that will allow for sleep staging according to the gold standard American Academy of 
Sleep Medicine criteria (46).  Participants will be monitored with PSG throughout the CRU 
admission. 
A  lumbar catheter and two IVs will be placed in the evening, with the goal of placement 
between 20:00-21:00, for collecting 6 ml of CSF every 2 hours for 36 hours (Figure 5) and 6ml of 
blood according to the specimen schedule (pg 7 of protocol). In order to efficiently use each 
participant’s samples, each individual will also receive a placebo medication (for Specific Aim 2) 
and an infusion of 13C6-leucine on Day 1 starting after catheter placement 0 (t=0) to label protein 
in vivo during intracellular translation in order to monitor Aβ kinetics (17, 40, 47).  Participants 
will be allowed to sleep as they are able after receiving study medication (placebo or suvorexant). 
Nursing staff will use dim red lights (safelights) when collecting CSF and blood in the dark.  The 
lumbar catheter ports will be placed on the outside of the gown sleeve for easy access to 
minimize disturbance during fluid collection.  Participants will then sleep until final awakening in 
the morning.   
During Day 2, all participants will be in well-lit rooms with regular monitoring for staying 
awake and naps will not be permitted.  At 21:00 on Day 2 (t=24), all participants will follow the 
same sleep routine except that there will be no infusion of labeled 13C6-leucine.  All participants 
will again receive placebo for the second night.  The IVs and lumbar catheters will be removed 
following the last CSF collection (t=36). Afterwards, participants will be monitored at the 
Clinical Research until discharge at approximately 17:00.  Aβ kinetics will be quantified by mass 
spectrometry (MS). 
 
Aim 2:  To determine the effect of pharmacologic sleep induction on CNS Aβ kinetics in 
individuals with poor sleep efficiency. 
45 participants with sleep efficiency <85% measured by actigraphy will be admitted to the 
CRU in the afternoon (Day 1). All participants will have their sleep monitored with PSG 
throughout the study as described in Aim 1.  A lumbar catheter and two IVs will be placed in the 
evening, with the goal of placement between 20:00-21:00,  for collecting 6 ml of CSF and 6 ml of 
blood according to the specimen schedule (pg 7 of protocol). Following catheter placement on 
Day 1 (t=0), all participants will start an infusion of labeled 13C6-leucine to label proteins in vivo 
during intracellular translation in order to monitor Aβ kinetics (17, 40, 47). 
45 participants will be randomized to receive a placebo, 10 mg of suvorexant, 20 mg of 
suvorexant during the CRU stay. Suvorexant is a dual orexin receptor antagonist that is approved 
by the Food and Drug Administration (FDA) for the treatment of insomnia.  Suvorexant is also a 
drug with the same mechanism of action as was used in experiments to decrease Aβ with sleep in 
mice (8), therefore this will be a direct translation of this finding.  Further, genetic manipulation 
of the orexin system to alter the sleep-wake cycle has been shown to drive Aβ pathology (51).  
FDA-approved doses of suvorexant range from 5-20 mg.  The drug’s mechanism of action is 
to block orexin-A and orexin-B receptors.  The orexin neuropeptide acts in the brain to promote 
wakefulness.  Through antagonism of this system, sleep is induced. In a phase IIb randomized, 
double-blind, placebo-controlled study of patients with primary insomnia, suvorexant 10 mg 
increased sleep efficiency from 65.1% at baseline to 82.9% at night 1 and 84.4% at one month 
(48).  Placebo-treated subjects increased sleep efficiency from 65.9% at baseline to 76.8% at 
night 1 and 77.8% at one month.   
Participants will be allowed to sleep as they are able immediately with the lights turned 
off after medication dispensation (placebo or suvorexant). Nursing staff will use dim red 
lights (safelights) when collecting CSF and blood in the dark. The lumbar catheter ports 
will be placed on the outside of the gown sleeve for easy access to minimize disturbance 
during fluid collection. Participants will then sleep until final awakening the morning. 
During Day 2, all participants will be in well-lit rooms with regular monitoring for 

5 
Version  15_03MAR2020 
staying awake and naps will not be permitted.  On Day 2 (t=24), all participants will 
follow the same sleep routine except that there will be no infusion of labeled 13C6-leucine. 
Participants will receive the same placebo or suvorexant dose as the previous night 
(Figure 5). The IVs and lumbar catheters will be removed following the last CSF 
collection (t=36).. Afterwards, participants will be monitored at the Clinical Research 
until discharge at approximately 17:00.  Aβ kinetics will be quantified by MS. 
 
  
 
 
Statistical Analysis and Power Calculation:  All participants will be screened to determine if 
they have good or poor sleep efficiency as described above.  15 participants with good sleep 
efficiency will be treated with placebo (Aim 1).  45 participants with poor sleep efficiency will be 
randomized to either placebo (N=15) (Aim 1) or suvorexant 10 mg (N=15) or suvorexant 20 mg 
(N=15) (Aim 2).  Change in CNS Aβ40 and Aβ42 production, clearance, and concentration in 
placebo-treated participants with poor sleep efficiency will be compared to placebo-treated 
participants with good sleep efficiency (Aim 1) and individuals with poor sleep efficiency treated 
with suvorexant (Aim 2) using a repeated measures analysis of variance (RM ANOVA), or 
repeated measures analysis of covariance (RM ANOCOVA) when covariates such as age are 
included in the analysis (49). Correction for multiple comparisons will be performed.  A main 
question is whether the production rate of CSF Aβ during the production phase differs between 
subjects with good or poor sleep efficiency, or treated with drug, that will be statistically tested by 
appropriate interactions between subjects groups and time in the RM ANOCOVA. The average 
concentration of CSF Aβ over the entire time course during the sleep period will be tested by the 
main effects of subjects’ groups, adjusting for the possible effects of age. Other parametric mixed 
effects models incorporating the typical sinusoidal profile over time will also be considered in the 
analyses. These analyses will be implemented by PROC MIXED/SAS or SPSS (50).  
To determine the sample size, I performed an a priori calculation with two-tailed t-tests to 
detect a difference between two independent means (two groups) for the number of subjects 
needed to find a difference in the AUC for both Aβ40 and Aβ42 during the 10-hour sleep period.  
With the preliminary data for control (good and poor sleep efficiency) and all sleep-induced 
participants, the mean and standard deviation of Aβ40 and Aβ42 AUCs (pM*hr) during the 10-
hour period from 23:00-09:00 were used for the power calculation (see Table 1:  “Control – Poor 
Sleepers (N=4)”, “Control – Good Sleepers (N=3)”, and “Sleep-Induced (N=8)”).  We will be 
able to detect similar pM*hr differences as from the preliminary data between all groups and all 
Aβ isoforms with 13 participants in each group (effect size d range=1.17-1.57, α = 0.05, Power 
(1-β) = 0.8), therefore this study is adequately powered with 15 participants in each group. 
 
Alternative Approaches: We chose serial CSF collection via lumbar catheterization for the 
experimental approach because it provides the most detailed measures of Aβ kinetics and 
concentrations.  An alternative approach could be to perform 13C6-leucine labeling with one 
lumbar puncture performed after the sleep period; differences in Aβ kinetics could be inferred by 
percent labeling of Aβ.  However, with this approach the time relative to each participant’s final 
awakening may be variable for each participant (e.g. 08:00 vs. 09:00) and does not easily account 
for different sleep start times.  A larger sample size may also be required with this approach.  
Other potential problems for this study include participant recruitment and study completion.  
This study is intensive for participants.  However, our preliminary study is similarly intensive and 
we have been able to achieve participant recruitment and completion goals.  Screening 
participants by good and poor sleep efficiency may be more difficult than anticipated because 
participants will initially be referred from the community-based participant registry, Volunteers 
for Health, based on self-report and questionnaires.  These measures may not correlate with the 
sleep efficiency found by actigraphy.  If this occurs, we will need to screen more participants than 

6 
Version  15_03MAR2020 
we planned.  Even if this occurs, we expect that participant recruitment goals will be met through 
the >10,000 potential participants enrolled in Volunteers for Health.  Finally, our preliminary 
analysis and power calculation are based on relatively small numbers of participants.  An interim 
analysis will be performed to see if additional participants are needed and if it is feasible to 
recruit them. 
 
Future Directions: Treatment of AD is hypothesized to be most successful in the preclinical 
phase before Aβ deposition into insoluble extracellular amyloid plaques and intracellular tau 
aggregation into tangles causes significant cell and synaptic loss leading to the onset of cognitive 
impairment and dementia. This project tests the hypothesis that CNS Aβ kinetics and 
concentrations are increased with low sleep efficiency and modifiable with medication to improve 
sleep efficiency. The proposed studies not only will increase our understanding of the 
pathogenesis of AD, they may suggest innovative AD prevention and treatment approaches that 
involve sleep therapies in older individuals with poor sleep quality. If successful, future studies 
will include an interventional trial to prevent amyloidosis (or slow amyloid growth) in those 
identified by clinical criteria.  Such a prevention trial could dramatically impact the incidence and 
prevalence of AD. Even if we are unable to decrease Aβ with the drug intervention, valuable 
information on the biology and pathophysiology of sleep-induced Aβ increases will be learned.  
From this study, alternative strategies (drugs, behavioral, environmental) may be taken to prevent 
sleep-induced increases in Aβ.  Sleep problems are common in older adults and nearly ALL older 
adults have changes in sleep architecture, suggesting that improving sleep efficiency in older 
adults may have broad application. Further, these studies may launch a novel field of research 
that identifies new targets for AD treatment.  
 
PROTECTION OF HUMAN SUBJECTS:  
1. Risks to Human Subjects 
A. Human Subjects Involvement, Characteristics, and Design 
Justification for human subject involvement: Alzheimer Disease (AD) is a current and growing 
public health problem characterized by progressive cognitive impairment resulting in dementia.  
AD is estimated to afflict millions of people in the coming decades.  Multiple lines of evidence 
suggest a role for sleep disturbances in the development of AD.  Further, there is evidence in 
mice that improving sleep parameters such as sleep efficiency (i.e. sleep quality) may prevent the 
initial pathological changes seen in the brain with AD.  These findings need to be replicated in 
humans if sleep interventions are to be deployed to prevent or delay AD.  In this study, I propose 
to translate the findings to humans that improving sleep efficiency has similar effects as in mice.  
The specific objective of this study is to translate basic science findings to humans for the long-
term improvement in human health, therefore the proposed study must be carried out in human 
subjects.   
 
Subject population characteristics: The goal is to enroll healthy, cognitively normal adults 45-65 
years old with no medical comorbidities that would affect the risk of AD and with no conditions, 
medications, or substance use that may affect outcome measures or contraindicate study 
procedures (e.g. cerebrospinal fluid (CSF) amyloid- (A) levels obtained by lumbar catheter).  
Participants will be recruited from the Volunteers for Health registry of >10,000 research study 
volunteers maintained at Washington University.  Individuals from both genders and any race or 
ethnicity will be included.  Minors will not be included because AD does not occur in individuals 
<18 years old, even if predisposed to develop AD through an autosomal dominant mutation.  
Further, it is not known if the diurnal Aβ pattern is present in children.  The relevance of 
determining if sleep alters Aβ in children to the pathogenesis of a neurodegenerative disorder that 
will potentially develop decades later is also unknown at this time. As a result, we will not 
include any children in this study.  Individuals older than 65 years will not be included in this 

7 
Version  15_03MAR2020 
study due to the decrease seen in the Aβ diurnal pattern with age. 
• 
Inclusion criteria: 
o Age 45-65 years 
o Any sex 
o Any race/ethnicity 
o Mini-Mental Status Examination score (MMSE) ≥ 27 [Ref. 42] 
o Sleep efficiency measured by actigraphy – this will be determined following 
enrollment and participants not meeting this criterion will be excluded from 
further participation in the study 
▪ 
Good sleep quality group:  Sleep efficiency > 85% [Aim 1] 
▪ 
Poor sleep quality group:  Sleep efficiency < 85% [Aims 1 and 2] 
• 
Exclusion criteria: 
o Cognitive impairment as determined by history of MMSE < 27 
o Inability to speak or understand English 
o Any sleep disorders other than insomnia 
▪ 
No history of sleep-disordered breathing and STOP-Bang score > 3 
▪ 
History or reported symptoms suggestive of restless legs syndrome, 
narcolepsy or other sleep disorders 
o Sleep schedule outside the range of bedtime 20:00-midnight and waketime 
04:00-09:00 
o Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to 
lidocaine or disinfectant; prior central nervous system or lower back surgery) 
o Cardiovascular disease requiring medication except for controlled hypertension  
(PI discretion) 
o Stroke 
o Hepatic or renal impairment 
o Pulmonary disease (PI discretion) 
o Type 1 diabetes 
o HIV or AIDS 
o Neurologic or psychiatric disorder requiring medication (PI discretion) 
o Suicidal ideations 
o Alcohol or tobacco use (PI discretion) 
o Use of sedating medications (PI discretion) 
o Inability to get out of bed independently 
o Abnormal movement of the non-dominant arm (would affect actigraphy data in 
unpredictable ways) 
o  In the opinion of the investigator, the participant should be excluded due to an 
abnormal physical examination.  
o Current pregnancy 
o Body Mass Index >35 
o History of migraines (PI discretion) 
o History of drug abuse in the last 6 months 
o 
History or presence of any clinically significant medical condition, behavioral or 
psychiatric disorder (including suicidal ideation), or surgical history based on 
medical record or patient report that could affect the safety of the subject or interfere 
with study assessments or in the judgment of the PI participant is not a good 
candidate. 
o Urinary or fecal incontinence 
o 
Difficulty sleeping in unfamiliar environment (good sleep quality group only) 
 
 

8 
Version  15_03MAR2020 
 
 For Aim 1, we will enroll two groups:15 participants with good sleep quality (sleep efficiency 
by actigraphy > 85%) and 15 participants with poor sleep quality (sleep efficiency by actigraphy 
< 85%).  All participants in Aim 1 will receive a placebo generated by the investigational 
pharmacy at Barnes-Jewish Hospital.  For Aim 2, an additional 30 participants with poor sleep 
quality (sleep efficiency by actigraphy < 85%) will be recruited and will receive either suvorexant 
10 mg or suvorexant 20 mg, a dual orexin receptor antagonist approved by the Food and Drug 
Administration (FDA) for the treatment of insomnia (approved doses 5-20 mg).  This group will 
be compared to the 15 participants with poor sleep quality in Aim 1 who received placebo.  
Participants who have poor sleep efficiency will be randomized to either placebo or suvorexant.  
There will be a total of 60 participants who complete the study. 
 
Sampling plan and justification:  
• 
Power calculations in the “Statistical Analysis and Power Calculation” portion of the 
research plan were based on preliminary data about the area under the curve differences 
in A during a 10-hour sleep period (23:00-09:00) in participants with different sleep 
efficiency. Due to concerns about recruitment if participants have to repeat the study, the 
study power calculation is based on each participant completing the study once without 
repeating.  15 participants are required for each study arm (total N=60). 
• 
Children will be excluded and age range will be limited to 45-65, as detailed in the 
previous section “Subject population characteristics”. 
 
Vulnerable populations: We will not enroll participants from vulnerable populations. 
 
Assignment to a study group: Participants with good sleep efficiency will not be randomized but 
will be placed in the “good sleep efficiency” group for Aim 1 and receive placebo.  Participants 
with poor sleep efficiency will be randomized to receive their placebo (Aim 1) or suvorexant 
(Aim 2) at the research unit admission.  The 45 participants in the poor sleep efficiency group 
will be randomized to receive placebo (15 participants) or suvorexant 10 or 20 mg (30 
participants). 15 participants will receive 10 mg of suvorexant for two nights and 15 participants 
will receive 20 mg of suvorexant for two nights. In addition to being a FDA approved drug for 
the treatment of insomnia, suvorexant is also a drug with the same mechanism of action as was 
used in experiments to decrease Aβ with sleep in mice, therefore this will be a direct translation 
of this finding.  FDA approved doses range from 5-20 mg.  The drug’s mechanism of action is 
to block orexin-A and orexin-B receptors.  The orexin neuropeptide acts in the brain to promote 
wakefulness.  Through antagonism of this system, sleep is induced. In a phase IIb randomized, 
double-blind, placebo-controlled study of patients with primary insomnia, suvorexant 10 mg 
increased sleep efficiency from 65.1% at baseline to 82.9% at night 1 and 84.4% at one month.  
Placebo-treated subjects increased sleep efficiency from 65.9% at baseline to 76.8% at night 1 
and 77.8% at one month [Ref. 48].   
 
Collaborating sites: None 
 
B. Sources of Materials 
Specimens, records, or data: We will obtain the following from our participants (de-identified) 
• 
Cerebrospinal fluid (CSF) specimens: Each participant regardless of study aim or group 
will have an indwelling lumbar catheter placed for the collection of CSF every 2 hours 
for 36 hours (hours 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36).  At 
each time point, 6 ml of CSF will be collected.  At the end of the study an additional 2 ml 
of CSF (when available) will be sent to the lab to check for any signs of infection.  

9 
Version  15_03MAR2020 
Therefore, a total of 116 ml of CSF will be collected from each participant over 36 hours.  
It is expected that the catheter will fail to draw CSF during the study for some 
participants.  This will result in missing CSF samples and missing CSF safety labs.   
• 
Blood specimens:  Each participant will have an intravenous (IV) catheter placed for 
collection of blood.  At the start of the study, blood will be collected 5, 10, 15, and 
30 minutes after the lumbar catheter placed.  Then, blood will be collected every 
30 minutes until hour 4. After hour 4, blood will be collected every 2 hours until 
hour 12. After hour 12, blood will be collected less frequently every 4 hours to 
hour 36.  Approximately 1-3 teaspoons of blood will be collected at 22 time 
points over 36 hours.  The total amount of blood taken over 24 hours is 120-240 ml 
(half of a standard blood donation).   
• 
Polysomnogram recordings to determined sleep stages will be obtained from all 
participants.  This includes standard electrodes for electroencephalography, 
electromyogram, and electrooculogram.  These recordings are not identifiable. 
• 
Actigraphy recording will be obtained from participants. This is a measure of motion in 
the wrist. These data are not identifiable. 
• 
Physical exam data including blood pressure, heart rate, respiratory rate, height, weight, 
and any abnormalities on physical exam. 
 
Data from human subjects: Our participants will provide the following data: 
• 
Name, date of birth, phone number, mailing address, and email (if they want). These are 
for the purposes of proper identification for the study and communication about research 
activities. Additionally, social security number is collected only for purposes of 
participant reimbursement. These data are stored separately from all other data. 
• 
Answers to screening questions for inclusion/exclusion criteria 
• 
Demographic information: age in years, sex, race/ethnicity, education, handedness 
• 
Medical history: Comorbidities, surgeries, medications, allergies, alcohol use 
• 
Mini-Mental Status Exam  
• 
Insomnia Severity Index 
• 
STOP-Bang Questionnaire 
• 
Sleep diary filled out while wearing actigraphy 
• 
Stanford Sleepiness Scale 
• 
Morning/Eveningness Questionnaire 
• 
Psychomotor vigilance testing 
 
Access to individually identifiable private information about human subjects: The only 
individually identifiable private information about human subjects are name, date of birth, phone 
number, mailing address, email, and social security number (latter only for participant 
reimbursement). These are stored separately from the rest of the data, which are labeled with a 
random number code only. Only team members trained in the protocol and are approved by the 
Human Research Protection Office (HRPO) will have access to private identifiable information, 
including the Principal Investigator, research coordinator/polysomnographic technicians, and the 
mentor.  
 
C. Potential risks 
Lumbar Catheter 
1. Discomfort during the procedure is common and mild.  Some people may have 
discomfort sitting in the same position for the duration of the lumbar catheter placement. 
Lidocaine will be used for local anesthesia, which feels like a small pinch followed by 

10 
Version  15_03MAR2020 
burning sensation (<10 seconds). There is pressure but not pain during the insertion of the 
lumbar puncture needle. During the lumbar catheter procedure, participants may 
experience momentary (<1 second) cramping or pain in a leg, due to the needle or the 
catheter briefly touching a floating nerve ending.  
2. Back soreness is common and mild.  Some people have soreness of the area where the 
needle and catheter were inserted, especially when the lidocaine wears off. This soreness 
resolves by itself over 2-3 days. 
3. Feeling faint is common and mild.  As with any medical procedure, some people feel 
faint. This is a normal response and is not a physical effect of the needle.  
4. Post-lumbar catheter headache occurs frequently (50-80% of participants) and is mild to 
moderate. Another possible symptom is ringing in the ears.  Individuals may have a 
headache following placement of a lumbar catheter, due to the decreased volume of CSF. 
For the majority of individuals, the headache resolves when the catheter is removed.  
Occasionally (30% or less), this headache persists after removal of the catheter and 
requires treatment with a “blood patch.”   
5. Bleeding is extremely rare, but is moderate to severe when it occurs. In individuals with 
problems of blood clotting, a lumbar catheter may cause a large amount of bleeding.  
6. Infection is an extremely rare risk of a lumbar catheter and can be moderate-to-severe.  
Very rarely, the lumbar puncture needle and catheter may introduce pathogens internally, 
leading to infection. 
 
Intravenous Catheter 
1. Discomfort from minor pain, bleeding, bruising, or swelling caused by the needle or 
intravenous catheter are common and mild.   
2. Bruising at the phlebotomy site is infrequent and mild.  Some individuals may have bruising 
due to leakage of a small amount of blood from the vein into the surrounding tissue. This will 
spontaneously resolve.  
3. Feeling faint is common and mild.  As with any medical procedure, some people feel faint. 
This is a normal response and is not a physical effect of the needle. 
 
Suvorexant 
1. Somnolence and confusion are common, mild side effects of suvorexant in participants who 
wake up within 4-6 hours after taking the drug.  This is an expected effect of this drug given 
its mechanism of action.  However, somnolence may be severe in participants with 
compromised respiratory function; therefore obstructive sleep apnea and chronic obstructive 
pulmonary disease are exclusion criteria. 
2. Next day drowsiness is another common, mild side effect of suvorexant.  Participants will be 
monitored in the Clinical Research Unit prior to discharge and will be assessed for level of 
alertness with a Stanford Sleepiness Scale and psychomotor vigilance testing performed upon 
admission and at the time of discharge.  The principal investigator will evaluate the 
participant and review these measures prior to approving discharge. 
3. Additional mild and common reactions to suvorexant include: headache, dizziness, abnormal 
dreams, diarrhea, dry mouth, and cough. 
4. Abnormal sleep behaviors, such as sleep walking, is rare and mild-to-moderate.  All 
participants will take suvorexant on the Clinical Research Unit at Washington University that 
has 24 hours a day nursing coverage monitoring the participants. 
5. Suvorexant may interact with multiple medications including alcohol, azole antifungals, 
antibiotics, nefazodone, antiretrovirals, conivaptan, aprepitant, diltiazem, iimatinib, 
verapamil, rifampin, carbamazepine, phenytoin, and digoxin.  The principal investigator will 
evaluate participants for potentially interacting medications and participants will be excluded 
from the study if the interacting drug(s) cannot be discontinued. 

11 
Version  15_03MAR2020 
6. Very rare:  For all individuals, but primarily in depressed participants treated with sedative-
hypnotics, worsening of depression and suicidal tendencies have been reported. 
 
Actigraphy 
1. Irritation of skin from strap of actigraph is very rare and mild.  Some individuals with very 
sensitive skin may have irritation of their skin from the actigraph strap. 
 
Polysomnogram (Sleep study) 
1. Irritation of skin from electrodes used during study is rare and mild.  Skin needs to be cleaned 
before adhesive is applied for the electrodes. Some individuals with sensitive skin may have 
irritation of their skin.  
2. Worse sleep quality is common and mild.  People usually do not sleep as well in an 
unfamiliar environment. Therefore participants may be more tired than usual the next day.  
 
Bedrest 
1.  There is risk of feeling dizzy, lightheaded, or whoozy upon standing after 60 hours of bed rest.  
This is common and mild.   
 
Privacy/confidentiality 
1 
Breach of privacy/confidentiality (very rare, severity varies): A risk in any research study is 
that confidential information about participants may be accidentally disclosed.  
 
2. Adequacy of Protection Against Risks 
A. Recruitment and Informed Consent  
Recruitment: Human subjects will be recruited from Volunteers for Health, a community-based 
registry of >10,000 individuals.  We will develop advertisements targeting symptoms of 
insomnia, and poor and good sleep quality to be sent to this registry.  Potential participants can 
indicate their interest in this study through an online system, in which case their name and contact 
information is sent to the principal investigator, or they can call the phone number that is on the 
advertising materials. 
Consent: Two separate consent processes are required, one for an initial phone screen to assess if 
participants are likely to meet inclusion/exclusion criteria for the study, and a second formal 
written consent. No waivers of elements of consent will be sought. 
• 
Phone screen consent: Because the initial phone screen contains questions that involve 
protected health information, verbal consent is obtained prior to going through the screen. 
The Washington University HRPO will review and approve a phone script for verbal 
consent, which includes (1) A statement that the phone screen is for research, (2) purpose 
of the phone screen, (3) expected duration of phone screen, (4) description of the phone 
screen, (5) identification of any procedures which are experimental, (6) description of 
risks and benefits, (7) disclosure of alternatives (i.e. not doing phone screen), (8) how 
confidentiality of records will be maintained, (9) a statement that participation is 
voluntary and not participating will involve no penalty or loss of benefits to which the 
person is otherwise entitled. 
• 
Consent for enrollment in study: Potential subjects are mailed a copy of the consent 
document to review and discuss with other individuals (if desired) prior to an in-person 
consent process. Consent will take place in a private exam room at the Washington 
University Sleep Medicine Center or the Neurology Clinical Research Unit (NCRU). 
Only members of the research team who have had training and are approved by the 
Washington University HRPO (including PI) may participate in the consent process. 
Information in the consent document includes: (1) A statement that the study is for 
research, (2) purpose of the research, (3) expected duration of study participation, (4) 

12 
Version  15_03MAR2020 
description of the research procedures, (5) identification of any procedures which are 
experimental, (6) description of risks and benefits, (7) disclosure of alternatives, (8) how 
confidentiality of records will be maintained, (9) a statement that participation is 
voluntary and not participating will involve no penalty or loss of benefits to which the 
person is otherwise entitled. Potential participants may ask questions either beforehand 
by phone or during this face-to-face visit, before deciding to enroll in the study. After all 
questions have been answered, and if the person wants to enroll in the study, the consent 
process will be finalized by both participant and research team member signing the 
consent document. Every participant is provided with a copy of the signed consent 
document. 
 
B. Protections Against Risk  
Lumbar catheter 
1. Discomfort during the procedure: To minimize discomfort, participants will sit at the edge of 
the bed with supports and pillows to keep them in an ergonomic position. Lidocaine will be 
used for local anesthesia. Only physicians experienced in performing lumbar catheters will 
perform this procedure. 
2. Back soreness: Participants are provided with information sheets on using heat, stretching, 
and acetaminophen if back soreness occurs. 
3. Feeling faint: If a participant feels faint, s/he will be assisted in lying down in the bed until 
the feeling has passed. The lumbar catheter can be performed with participants lying down on 
their side, in this case.  
4. Post-lumbar catheter headache: This risk will be minimized by having the participants lie in 
bed with their heads down (the Trendelenburg position) for one hour after the catheter is 
removed.  Participants will remain in bed for 6-8 hours after the catheter is removed.  
Participants are also informed they can minimize this risk by having caffeine after the lumbar 
catheter is removed, and drinking plenty of water throughout the study while the catheter is in 
place. If a post-lumbar catheter headache does occur, participants will be offered treatment 
with a “blood patch.” 
5. Bleeding: Individuals with this risk (blood clotting problems or taking anticoagulants) are 
excluded from participation in the study. 
6. Infection: Proper sterile technique will be used during all lumbar catheter placements.  At the 
end of the study immediately prior to the removal of the catheter, an additional 2 ml of CSF 
will be drawn, when available, and sent to the lab to check for any signs of infection.  
Further, participants are given a 24/7 phone number for a member of the research team after 
discharge from the Clinical Research Unit in case of complications. 
 
Intravenous catheter 
1. Discomfort during the procedure: Only physicians and nurses experienced in placing 
intravenous catheters will perform the procedure. 
2. Bruising at phlebotomy site: Discomfort from bruising can be alleviated by moist heat pack, 
which can be provided in the Clinical Research Unit.  
3. Feeling faint: If a participant feels faint, s/he will be assisted in lying down in the bed until 
the feeling has passed. Participants will be encouraged to drink plenty of water during the 
study, to minimize the chance of feeling faint. 
 
Suvorexant 
1. Somnolence and confusion:  Participants will be on the Clinical Research Unit throughout the 
study with 24-hour nursing coverage.  Participants will only take suvorexant in this 
monitored setting.  Nurses will be available to assist all participants if they wake up confused 
and somnolent during the night.  Further, the participants will be under constant video 

13 
Version  15_03MAR2020 
monitoring while in the Clinical Research Unit; this video is not recorded and is only 
viewable by the nursing staff.  Somnolence may be severe in participants with compromised 
respiratory function; therefore, obstructive sleep apnea and chronic obstructive pulmonary 
disease are exclusion criteria.  Suvorexant will be discontinued if somnolence and/or 
confusion is distressing to the participant or severe. 
2. Next day drowsiness:  Participants will be monitored in the Clinical Research Unit prior to 
discharge and will be assessed for level of alertness with a Stanford Sleepiness Scale and 
psychomotor vigilance testing performed upon admission and at the time of discharge.  The 
principal investigator will evaluate the participant and review these measures prior to 
approving discharge. 
3. Additional mild and common reactions to suvorexant include headache, dizziness, abnormal 
dreams, diarrhea, dry mouth, and cough:  Participants will be on the Clinical Research Unit 
throughout the study with 24-hour nursing coverage.  Participants will only take suvorexant 
in this monitored setting.  Nurses will be available to assist all participants if they develop 
these symptoms.  Suvorexant will be discontinued if reactions are distressing to the 
participant or severe. 
4. Abnormal sleep behaviors:  All participants will take suvorexant on the Clinical Research 
Unit at Washington University which has 24 hours a day nursing coverage monitoring the 
participants.  Participants will only take suvorexant in this monitored setting.  Nurses will be 
available to assist all participants if they develop these symptoms.  Further, the participants 
will be under constant video monitoring while in the Clinical Research Unit; this video is not 
recorded and is only viewable by the nursing staff.  Suvorexant will be discontinued if 
reactions are distressing to the participant or severe. 
5. Suvorexant may interact with multiple medications:  Participants taking medications that 
interact with suvorexant will be evaluated by the principal investigator.  If the potentially 
interacting medications cannot be discontinued, then the participants will be excluded from 
the study. 
6. Depressed mood and/or suicidal ideations:  All participants will be screened for suicidal 
ideations and psychiatric disorders.  All participants with psychiatric disease requiring 
medications will be excluded both to control this risk and also because psychiatric 
medications may interfere with sleep.  Participants will suicidal ideations will be excluded.  
This risk is also controlled because participants will only take suvorexant for 2 nights in the 
monitored setting of the CRU with 24 hours a day nursing coverage. 
 
Actigraphy 
1. Irritation of skin from strap of actigraph: Participants will be permitted to wear the actigraph 
over long sleeves or a wrist band, or they can remove the actigraph at any time. 
 
Polysomnogram (Sleep study) 
1. Irritation of skin from electrodes used during study: When possible, an alternative cleaning 
agent or adhesive will be used. If irritation is more than mild, that electrode will not be used 
for the study. 
2. Worse sleep quality: Participants will be allowed to nap until 17:00 before going home after 
the conclusion of the study. 
 
Privacy/confidentiality 
1. Breach of privacy/confidentiality:  
• 
All data will be labeled with a random number rather than with any identifiable 
information. All physical materials (such as paper, data storage disks, and biospecimens) 
will be stored in locked cabinets/freezers in a locked research area, accessible only to the 
research team. All electronic information will require a password and will be accessible 

14 
Version  15_03MAR2020 
only to the research team. Any paper or electronic information that could link a 
participant to the study (such as consent documents) will be stored separately from all 
other study materials, also in a secure manner that is accessible only to the research team. 
If a report or article is written about this study or the study data are shared with other 
researchers, it will be done in such a way that participants cannot be identified. 
• 
For individuals who give verbal consent for the Phone screen, and then do not “pass” the 
screening questions, their phone screen will be shredded, and no information is kept 
about them. 
 
Protections for research involving vulnerable populations: This project does not involve 
vulnerable populations. 
 
Plan for adverse events: Response to an adverse event or risk will differ based on the type and 
severity of the event. A Data Safety Monitoring Committee (DSMC) will serve to mitigate these 
risks and ensure a formal process for dealing with adverse events. 
• 
Data Safety Monitoring Committee: A DSMC consisting of experts in the study 
procedures and the effects of sleep disorders on cardiac and psychiatric morbidities has 
been established for the proposed study.  
o Qualified individuals monitoring the study: The DSMC members have 
substantial experience and expertise in this area of research and in clinical 
research, and are qualified to monitor the study. 
o The DSMC will meet prior to enrollment of any participants, to review study 
procedures and potential adverse events, and then provide guidance on HRPO 
application and consent/informational materials.  
• 
Web-Based Instruction on Conducting Human Research: In accordance with the NIH 
policy effective October 1, 2000, this is to certify that Washington University key 
personnel involved in the design and conduct of the human subjects research aspect of 
this proposal have been educated on the protection of human research participants. An 
interactive web-based program that provides information on conducting human research 
and the informed consent process is organized into five modules. These modules include 
detailed information, examples and exercises related to basic principles, history, consent 
form process, and after approval requirements such as continuing review and adverse 
events. 
• 
Review of adverse events: All personnel who will be in contact with participants and/or 
data are prepared to identify adverse events and have been instructed to report their 
occurrence immediately to the principal investigator. 
• 
Definition: An adverse event will be defined as any negative change in health related to 
study-related procedures. 
• 
Classification of Events: A Safety Documentation form will assess for details of any 
adverse events, severity, and relatedness to study procedures. 
• 
Data Collection Procedures for Adverse Events: At each visit and with each 
interaction/phone call, adverse events will be screened for and recorded. If any adverse 
events have occurred, these will be logged in the Safety Documentation form. 
• 
Reporting Procedures: The Safety Documentation form will be discussed during the 
DSMC meetings. The DSMC will meet according to participant completion goals (after 
15, 23, 30, 38, and 45 participants complete the study).  If a serious adverse event 
occurs, the DSMC will meet as soon as possible to determine the course of action. If the 
DSMC deems changes to the study are necessary for safety reasons, the study will halt 
immediately until the changes have been approved through the Washington University 
HRPO. 

15 
Version  15_03MAR2020 
• 
Criteria for stopping the study: Circumstances that would warrant stopping the study are 
not anticipated. However, should any circumstances arise that compromise the safety of 
the participants, they will be reported to the DSMC who will suspend research until 
appropriate safeguards allow continuation of the study. 
• 
Adverse Event Reporting Period: There will not be a set end-date for reporting adverse 
events.  
o Expected adverse events (i.e. are listed above and on consent forms) will be 
discussed at DSMC meetings. Also, they will be reported to the HRPO during 
annual renewals. 
o Unexpected serious adverse events will be reported within 10 days, per HRPO 
requirements. 
The only anticipated adverse events that would require medical intervention are: 
1. A post-lumbar catheter headache that does not resolve with 
conservative measures such as rest, hydration, and caffeine 
intake. This will be treated with “blood patch” in the Clinical 
Research Unit, at no cost to the participant. 
2. Side effects to suvorexant such as somnolence and confusion 
upon waking.  Risks from suvorexant are minimized with the 
inclusion/exclusion criteria and that participants will only 
receive the drug for 2 nights in the monitored setting of the 
Clinical Research Unit at Washington University.  If any severe 
adverse events occur on suvorexant, then the drug will be 
discontinued and the participant monitored closely. 
 
 
3. Potential Benefits of the Proposed Research to Human Subjects and Others 
Potential benefits to participants 
The only direct benefit to the participant is that they will be screened for sleep apnea with the 
STOP-Bang questionnaire and other sleep disorders by the history and examination of the 
principal investigator.  This may result in a diagnosis that may have been made later.  Participants 
who screen fail due to concerns for a sleep disorder like sleep apnea will be informed of the 
reason for exclusion, withdrawn from the study, and encouraged to follow-up with their primary 
care physician.  
 
Potential benefits to others 
Potential benefits to society will be knowledge of whether or not sleep modification can change 
CSF Aβ production and concentrations.  If CSF Aβ production and concentrations can be 
modified by improving sleep efficiency, then this opens up a new potential treatment option for 
the prevention or treatment of Alzheimer's disease from which they, or future AD patients, may 
benefit. 
 
Risks vs. benefits: The benefit of the knowledge to the gained in the study, as well as the personal 
benefit to participants, outweighs the risks in the study. Risks have been minimized to the greatest 
possible extent, while still achieving the scientific aims of the research study. 
 
4. Importance of the Knowledge to be Gained 
The knowledge to be gained in this study is very important because it is the first study directly 
assessing the relationship of poor sleep efficiency and A in a relevant human population. If this 
study is successful, it will lead to treatments targeting sleep for possibly delaying or reducing risk 
of AD. AD is a devastating neurodegenerative disorder characterized by progressive cognitive 
decline.  The public health impact of dementia is enormous with the number of individuals with 

16 
Version  15_03MAR2020 
AD projected to increase from 5 million Americans in 2010 to 13.5 million Americans in 2050.  
Even a modest reduction in the risk of AD would have a tremendous public health impact.  
Demonstrating that sleep alters Aβ may suggest innovative AD treatment approaches that involve 
sleep therapies. 
 
5. Data and Safety Monitoring Plan 
This study is a clinical trial, however it is not an NIH-defined phase III clinical trial.  Suvorexant 
is already FDA-approved for the treatment of insomnia.  This study will use suvorexant under the 
FDA-approved indication.  Comparisons are being made between poorly-sleeping treated 
(suvorexant) and untreated individuals (placebo). There is a Data Safety Monitoring Committee 
and monitoring plan as described in section “2.B Protections Against Risk” above.  Brendan 
Lucey, M.D., Randall Bateman, M.D., Phyllis K. Stein, Ph.D., and Yo-El S. Ju, M.D. will 
monitor the study for adverse events, adherence to the protocol, inclusion/exclusion criteria, and 
accrual/withdrawal rates.  All serious adverse events will be reported to the Washington 
University HRPO: a) death – immediately; b) life threatening with 7 calendar days; c) all other 
SAEs within 15 calendar days using the HRPO Reportable Event Form (SAE report).  Should 
there be an adverse event that occurs that increases the risks to the participants, the following 
steps will be taken: suspension of the study until risks are re-evaluated and discussed with the 
HRPO. Other reports that will be generated are yearly summary reports. These will be sent to the 
HRPO annually. 
 
Given that the study requires significant involvement from the participants, we have taken steps 
to make the study less taxing for participants. These steps include having nurses available in the 
CRU for assisting the research participants at all times and providing 24 hour/7 day/week access 
to study staff and physicians.  
 
All participants will be identified by a deidentified study number to protect patient 
confidentiality. Participants may be linked to the “sleep quality” study in Epic if they already 
have a record in the Epic system.  Spreadsheets listing the participants’ name and corresponding 
study number will be managed by the study coordinator, and will be stored in a password 
protected file behind the Neurology firewall. Only the research team will have access to this 
spreadsheet. Data monitoring and analysis will be performed by the principle investigator. Data 
will also be collected on any adverse events related to the study procedures.   
 
All data is electronically uploaded and locked in the Bateman laboratory’s database (Firebird 
2.1.4) blinded to clinical status and other variables. In collaboration with Dr. Bruce Patterson, an 
expert in modeling at 
Washington University, the Aβ stable isotope labeling kinetics (SILK) data will be analyzed with 
the compartmental model using the SAAM II modeling program blinded to clinical status and 
other variables. All statistical analyses will be conducted in collaboration with Dr. Chengjie 
Xiong, an expert in statistics at Washington University. All data is compared in a pre-specified 
fashion. All data and results will be available to other investigators upon request. 
 
 
6. ClinicalTrials.gov Requirements 
This study will be registered at ClinicalTrials.gov and the final study results will be reported on 
the website within 12 months of study completion.  This will enable registration of primary and 
secondary aims and allow for broadest publication in journals.